{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:46:31Z","timestamp":1782254791301,"version":"3.54.5"},"reference-count":38,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Study objective<\/jats:title>\n                    <jats:p>Complex pharmacotherapy in cancer patients increases the likelihood of drug-drug interactions (DDIs). Pharmacists play a critical role in the identification and management of DDIs. The aim of present study was to evaluate the role of pharmacist in identifying antifungal drug interactions in cancer patients and providing relevant recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>\n                      A retrospective, cross-sectional study was conducted to identify antifungal drug interactions over the period of 5 years (2019\u20132023) among cancer patients. Electronic medical record of 384 hospitalized patients receiving systemic antifungal therapy were reviewed. Severity of interactions and risk classification were made using UptoDate\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Lexidrug\n                      <jats:sup>TM<\/jats:sup>\n                      software. Pharmacists\u2019 recommendations regarding DDIs were also documented. Descriptive statistics and logistic regression were applied to interpret results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Antifungals were more frequently prescribed to adult patients (53.9%). Female cancer patients were significantly more likely to encounter DDIs than males (\n                      <jats:italic toggle=\"yes\">p\u2009<\/jats:italic>\n                      &lt;\u20090.003). Type of cancer and fungal infections were significantly associated with incidence of DDIs (\n                      <jats:italic toggle=\"yes\">p\u2009<\/jats:italic>\n                      &lt;\u20090.01;\n                      <jats:italic toggle=\"yes\">p\u2009<\/jats:italic>\n                      =\u20090.000). Pharmacist identified DDIs in 53.9% antifungal prescriptions with 22.2% classified as major interactions. A substantial proportion of these interactions involved voriconazole (40.1%). Majority of pharmacist's recommendations included dose optimization of voriconazole (10.4%), close monitoring of RFTs (8.9%) and withholding amphotericin (5.2%) during chemotherapy. All of the recommendations made by pharmacists were accepted by physicians (100%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings indicate that pharmacists identified DDIs in 53.9% of prescriptions and all of their recommendations were accepted by physicians. This highlights the critical role of pharmacists in detecting potential interactions, ensuring medication safety, and minimizing adverse effects associated with complex pharmacotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251316184","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T23:39:26Z","timestamp":1738193966000},"page":"837-845","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Antifungal-drug interactions in oncology: A cross-sectional study highlighting the role of pharmacists"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-8677","authenticated-orcid":false,"given":"Zunaira","family":"Akbar","sequence":"first","affiliation":[{"name":"The University of Lahore"},{"name":"Riphah International University, Lahore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4471-676X","authenticated-orcid":false,"given":"Muhammad","family":"Aamir","sequence":"additional","affiliation":[{"name":"The University of Lahore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-6347","authenticated-orcid":false,"given":"Zikria","family":"Saleem","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Rehan","family":"Khan","sequence":"additional","affiliation":[{"name":"Shaukat Khanum Memorial Cancer Hospital and Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S238166"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12318"},{"key":"e_1_3_3_4_2","first-page":"149","article-title":"Clinical hepatotoxicity associated with antifungal agents","volume":"16","author":"Kyriakidis I","year":"2017","unstructured":"Kyriakidis I, Tragiannidis A, Munchen S, et al. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf 2017; 16: 149\u2013165.","journal-title":"Expert Opin Drug Saf"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27915"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2649-7"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S254478"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Denning DW. Global incidence and mortality of severe fungal disease. The Lancet Infectious Diseases 2024.","DOI":"10.2139\/ssrn.4560971"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13151"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.772"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw391"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12751"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1273900"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac352"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(24)00225-0"},{"key":"e_1_3_3_16_2","article-title":"Highlights of pharmacist roles in hematopoietic cell transplantation and cellular therapy","volume":"4","author":"Shi HY","year":"2021","unstructured":"Shi HY, Tharnpanich T, Yu B. Highlights of pharmacist roles in hematopoietic cell transplantation and cellular therapy. Blood Cell Therapy 2021; 4: S8\u2013S13.","journal-title":"Blood Cell Therapy"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-019-00918-z"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab593"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216664201"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00109"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2301.161198"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1386167"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof9030381"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.riam.2014.11.006"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S80762"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.891336"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku053"},{"key":"e_1_3_3_28_2","first-page":"271","article-title":"Invasive fungal infection","volume":"116","author":"von Lilienfeld-Toal M","year":"2019","unstructured":"von Lilienfeld-Toal M, Wagener J, Einsele H, et al. Invasive fungal infection. Dtsch Arztebl Int 2019; 116: 271\u2013278.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_3_29_2","first-page":"175","article-title":"Potential of drug interactions among hospitalized cancer patients in a developing country","volume":"12","author":"Tavakoli-Ardakani M","year":"2013","unstructured":"Tavakoli-Ardakani M, Kazemian K, Salamzadeh J, et al. Potential of drug interactions among hospitalized cancer patients in a developing country. Iran J Pharm Res 2013; 12: 175\u2013182.","journal-title":"Iran J Pharm Res"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144637"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12493"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.11.025"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2162-5"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213509847"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-016-0382-6"},{"key":"e_1_3_3_36_2","first-page":"107815522312231","article-title":"Clinical significance of coadministration of moderate to strong CYP enzyme inhibitors with doxorubicin in breast cancer patients receiving AC chemotherapy","author":"Dawson AP","year":"2024","unstructured":"Dawson AP, Frick CD, Burd M, et al. Clinical significance of coadministration of moderate to strong CYP enzyme inhibitors with doxorubicin in breast cancer patients receiving AC chemotherapy. J Oncol Pharm Pract 2024: 10781552231223125. DOI: 10.1177\/10781552231223125","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.85207"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00629-21"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae184"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251316184","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251316184","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251316184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:50:14Z","timestamp":1782251414000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251316184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/10781552251316184"],"URL":"https:\/\/doi.org\/10.1177\/10781552251316184","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]}}}